Completed PHASE3 INTERVENTIONAL 2-arm NCT00660387

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations

Sponsor: AbbVie (prior sponsor, Abbott)

Conditions Advanced Parkinson's Disease

Interventions CADD-Legacy® 1400 ambulatory infusion pump J-tube Levodopa carbidopa intestinal gel (LCIG) Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets PEG tube Placebo (PBO) oral capsules Placebo Gel

Updated 6 times since 2017 Last updated: Jan 12, 2015 Started: Dec 31, 2009 Primary completion: Oct 31, 2011 Completion: Oct 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Advanced Parkinson's Disease and is currently completed. AbbVie (prior sponsor, Abbott) leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie (prior sponsor, Abbott)
Quintiles, Inc.

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Auckland, New Zealand , Birmingham, United States , Chicago, United States , Christchurch, New Zealand , Cincinnati, United States , Cleveland, United States , Fountain Valley, United States , Hamilton, New Zealand , Kirkland, United States , Lexington, United States and 4 more locations